Clinical Trials Browser

Phase 3 × Lymphoma, T-Cell, Cutaneous × Vorinostat × Clear all

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01386398 2015-01-21

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3 Withdrawn

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous